Literature DB >> 31643137

Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.

Ling-Yi Feng1,2, Kiyoshi Wada3, Heesun Chung4, Eunyoung Han5, Jih-Heng Li1,2,6,7.   

Abstract

For decades, the three United Nations drug conventions have served as the basis for member states' obligations and international cooperation on drug control. However, the emergence of new psychoactive substances (NPSs) poses a new risk to public health and a challenge to drug policy because of their unknown toxicological effects and easy modification of chemical structures to shun legal control. So far, there is no international consensus on legislative control of NPSs. Therefore, we compared the legislative management on NPS control among Taiwan, South Korea, and Japan. Drug-related information was obtained from the authorities of these three countries. The results indicate that despite geographic proximity and similar legal attitudes toward illegal drug use, the legislative criteria, and responses for NPS control in these three countries were quite different. Ketamine has been the major used NPS in Taiwan but seldom found in South Korea and Japan. The difference in the number of controlled NPSs in Taiwan (91) and South Korea (245) might be due to the implementation of temporary designation systems and analog controls in South Korea. The recent surge of newly controlled NPSs in Japan was because of the promulgation of designated drug regulation and subsequent control of "dangerous drugs." Although NPS use has become a potential social and medical problem among these three countries, the outcomes of NPS legislation control remain to be scrutinized. To minimize harm from NPS use, development of legislative mechanism(s) on NPS scheduling is the first step for early identification and control of NPS problems.
© 2019 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University.

Entities:  

Keywords:  Japan; South Korea; Taiwan; new psychoactive substance (NPS) legislation

Mesh:

Substances:

Year:  2019        PMID: 31643137     DOI: 10.1002/kjm2.12140

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  5 in total

1.  Management of Treatment-Resistant Depression in Real-World Clinical Practice Settings Across Asia.

Authors:  Gang Wang; Changsu Han; Chia-Yih Liu; Sandra Chan; Tadafumi Kato; Wilson Tan; Lili Zhang; Yu Feng; Chee H Ng
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-03       Impact factor: 2.570

Review 2.  New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.

Authors:  Maria Rosaria Varì; Giulio Mannocchi; Roberta Tittarelli; Laura Leondina Campanozzi; Giulio Nittari; Alessandro Feola; Federica Umani Ronchi; Giovanna Ricci
Journal:  Int J Environ Res Public Health       Date:  2020-11-23       Impact factor: 3.390

3.  Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression- an Asian Sub-group Analysis from the SUSTAIN-2 Study.

Authors:  Hong Jin Jeon; Po-Chung Ju; Ahmad Hatim Sulaiman; Salina Abdul Aziz; Jong-Woo Paik; Wilson Tan; Daisy Bai; Cheng-Ta Li
Journal:  Clin Psychopharmacol Neurosci       Date:  2022-02-28       Impact factor: 2.582

4.  New psychoactive substances in Taiwan: The current situation and initiative for rational scheduling.

Authors:  Wen-Jing Yu; Linda Cottler; Jih-Heng Li
Journal:  J Food Drug Anal       Date:  2021-03-15       Impact factor: 6.157

Review 5.  A review of synthetic cathinones emerging in recent years (2019-2022).

Authors:  Patryk Kuropka; Marcin Zawadzki; Paweł Szpot
Journal:  Forensic Toxicol       Date:  2022-09-15       Impact factor: 2.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.